Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey. Show more
Location: 30 Technology Drive, Warren, NJ, 07059, United States | Website: https://www.aquestive.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
328.8M
52 Wk Range
$2.12 - $5.80
Previous Close
$3.31
Open
$3.31
Volume
1,075,204
Day Range
$3.28 - $3.50
Enterprise Value
299.3M
Cash
68.66M
Avg Qtr Burn
-12.19M
Insider Ownership
5.62%
Institutional Own.
48.76%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details Parkinson’s disease (OFF Episodes / motor fluctuations) | Approved Quarterly sales | |
SUBOXONE (buprenorphine/naloxone) Details Opioid addiction | Approved Quarterly sales | |
Exservan™ (riluzole) Oral Film Details Amyotrophic Lateral Sclerosis (ALS) | Approved Quarterly sales | |
ZUPLENZ (ondansetron) Details Nausea and vomiting | Approved Quarterly sales | |
PDUFA Approval decision | ||
AQST-108 (epinephrine) Topical Gel Details Alopecia areata | Phase 2a Initiation | |
AQST-119 Details Erectile dysfunction
| Failed Discontinued |